SECURITY AGREEMENTSecurity Agreement • March 21st, 2005 • Grant Life Sciences, Inc. • In vitro & in vivo diagnostic substances • New York
SECURITY AGREEMENT, dated as of March 15, 2005 (this “Agreement”), among Grant Life Sciences, Inc., a Nevada corporation (the “Company” or the “Debtor”) and the holder or holders of the Company’s 8% Senior Secured Notes due June 15, 2005 in the aggregate principal amount of up to $200,000 (the “Notes”), signatory hereto, their endorsees, transferees and assigns (collectively referred to as, the “Secured Parties”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • March 21st, 2005 • Grant Life Sciences, Inc. • In vitro & in vivo diagnostic substances
This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 15, 2005, among Grant Life Sciences, Inc., a Nevada corporation (the “Company”), and the purchasers signatory hereto (each such purchaser is a “Purchaser” and all such purchasers are, collectively, the “Purchasers”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 21st, 2005 • Grant Life Sciences, Inc. • In vitro & in vivo diagnostic substances • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of March 15, 2005 among Grant Life Sciences, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT To Purchase 250,000 Shares of Common Stock of Grant Life Sciences, Inc.Security Agreement • March 21st, 2005 • Grant Life Sciences, Inc. • In vitro & in vivo diagnostic substances
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, DCOFI Master LDC (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Grant Life Sciences, Inc., a Nevada corporation (the “Company”), up to 250,000 shares (the “Warrant Shares”) of Common Stock, $0.001 par value, of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
8% SENIOR SECURED NOTE DUE JUNE 15, 2005Convertible Security Agreement • March 21st, 2005 • Grant Life Sciences, Inc. • In vitro & in vivo diagnostic substances • New York
THIS NOTE is a duly authorized and issued 8% Senior Secured Note of Grant Life Sciences, Inc., a Nevada corporation, having a principal place of business at 5511 Capital Center Drive, Suite 224, Raleigh NC 27606, (the “Company”), designated as its 8% Senior Secured Note, due June 15, 2005 (the “Note(s)”).
